VRCA Earnings

Quarterly EPS
$-4.88
Q3 2024
$-2.40
Q4 2024
$-1.03
Q1 2025
$0.02
Q2 2025
$-0.03
Q3 2025
$-0.57
Q4 2025
$-0.45
Q1 2026
$-0.62
Q2 2026
Latest Revenue5.9M
Latest Net Income-13153000
EPS & Revenue Trend
PeriodEPSRevenueNet IncomeRev YoYEPS YoY
Q2 2026-$0.625.9M-13153000-53.8%-3,200.0%
Q1 2026-$0.455.0M-9682000+46.1%+56.3%
Q4 2025-$0.575.1M-8074000+1,380.2%+76.3%
Q3 2025-$0.0314.3M-274000+905.4%+99.4%
Q2 2025$0.0212.7M204.0K+145.4%+100.5%
Q1 2025-$1.033.4M-9742000-10.1%+76.6%
Q4 2024-$2.40344.0K-16202000-82.7%+54.8%
Q3 2024-$4.88-1781000-22860000-161.1%+9.6%
Q2 2024-$3.705.2M-17186000
Q1 2024-$4.403.8M-20331000
Q4 2023-$5.312.0M-24614000
Q3 2023-$5.402.9M-24802000
Verrica Pharmaceuticals (VRCA) — Earnings